# Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

> **NCT00711243** · PHASE1,PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 59 (actual)

## Conditions studied

- Gastric Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** docetaxel
- **DRUG:** fluorouracil
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00711243
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04-20
- **Primary completion:** 2008-12-15
- **Final completion:** 2011-02-25
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00711243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00711243, "Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00711243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*